deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04660799

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients With CD20 Positive Diffuse Large B Cell Lymphoma

Sponsor: Hoffmann-La Roche

Conditions Lymphoma, Large B-Cell, Diffuse
Interventions Cyclophosphamide Diphenhydramine hydrochloride or alternative antihistamine Doxorubicin Paracetamol Prednisone Rituximab IV Rituximab SC Vincristine
Updated 21 times since 2021 Last updated: Sep 29, 2023 Started: Feb 24, 2021 Primary completion: May 23, 2022 Completion: Oct 11, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04660799, this PHASE2 trial focuses on Lymphoma, Large B-Cell, Diffuse and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 21 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Aug 2023 · 8 months · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Aug 2023 — Nov 2023 [monthly]

    Completed PHASE2

▶ Show 16 earlier versions

  1. Dec 2022 — Aug 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  4. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2022 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  8. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  9. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  10. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  11. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  12. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  13. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  14. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  15. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations